AQQRF (Aquarius Surgical Technologies) EBIT: $-0.55 Mil (TTM As of Dec. 2025)


What is Aquarius Surgical Technologies EBIT?

Aquarius Surgical Technologies AQQRF EBIT is $-0.55 Mil as of Dec. 2025. The stock has 4 warning signs investors should review.

Aquarius Surgical Technologies's earnings before interest and taxes (EBIT) for the three months ended in Dec. 2025 was $-0.35 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Dec. 2025 was $-0.55 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Aquarius Surgical Technologies's annualized ROC % for the quarter that ended in Dec. 2025 was -6.44%. Aquarius Surgical Technologies's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2025 was -10,830.77%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Aquarius Surgical Technologies's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2025 was -10.98%.

Aquarius Surgical Technologies  (OTCPK:AQQRF) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Aquarius Surgical Technologies's annualized ROC % for the quarter that ended in Dec. 2025 is calculated as:

ROC % (Q: Dec. 2025 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Sep. 2025 ) + Invested Capital (Q: Dec. 2025 ))/ count )
=-0.112 * ( 1 - 0% )/( (1.867 + 1.61)/ 2 )
=-0.112/1.7385
=-6.44 %

where

Invested Capital(Q: Sep. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=1.608 - 0.98 - ( 0.004 - max(0, 1.303 - 0.064+0.004))
=1.867

Invested Capital(Q: Dec. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=1.265 - 1.011 - ( 0.007 - max(0, 1.425 - 0.069+0.007))
=1.61

Note: The Operating Income data used here is four times the quarterly (Dec. 2025) data.

2. Joel Greenblatt's definition of Return on Capital:

Aquarius Surgical Technologies's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2025 is calculated as:

ROC (Joel Greenblatt) %(Q: Dec. 2025 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Sep. 2025  Q: Dec. 2025
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-1.408/( ( (0.026 + max(-0.92, 0)) + (0 + max(-0.949, 0)) )/ 2 )
=-1.408/( ( 0.026 + 0 )/ 2 )
=-1.408/0.013
=-10,830.77 %

where Working Capital is:

Working Capital(Q: Sep. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0.027 + 0.014 + 0.019) - (0.98 + 0 + 0)
=-0.92

Working Capital(Q: Dec. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(0.033 + 0.014 + 0.015) - (1.011 + 0 + 2.2204460492503E-16)
=-0.949

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Dec. 2025) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Aquarius Surgical Technologies's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Dec. 2025 )
=-0.548/4.993
=-10.98 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Aquarius Surgical Technologies EBIT Related Terms

Aquarius Surgical Technologies EBIT Historical Data

* Premium members only.

The historical data trend for Aquarius Surgical Technologies's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Aquarius Surgical Technologies EBIT Chart

Aquarius Surgical Technologies Annual Data
Trend Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25
EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only -1.17 -0.52 -0.38 -0.34 -0.60

Aquarius Surgical Technologies Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.12 -0.29 0.59 -0.50 -0.35

AQQRF vs ABT, SYK, MDT: EBIT Comparison

For the Medical Devices subindustry, Aquarius Surgical Technologies's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Aquarius Surgical Technologies EV-to-EBIT vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Aquarius Surgical Technologies's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Aquarius Surgical Technologies's EV-to-EBIT falls into.


Aquarius Surgical Technologies EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.55 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT →
What does a EBIT of $-0.55 Mil mean?
Aquarius Surgical Technologies (AQQRF) has a EBIT of $-0.55 Mil as of Dec. 2025. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Aquarius Surgical Technologies.
Is Aquarius Surgical Technologies' EBIT too high?
Aquarius Surgical Technologies' current EBIT is $-0.55 Mil.
How does Aquarius Surgical Technologies' EBIT compare to ABT and SYK?
Aquarius Surgical Technologies' EBIT of $-0.55 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Medical Devices & Instruments company?
A good EBIT depends on the Medical Devices & Instruments industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Aquarius Surgical Technologies. Aquarius Surgical Technologies's current EBIT is $-0.55 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Aquarius Surgical Technologies stock overvalued right now?
Aquarius Surgical Technologies (AQQRF) has a current EBIT of $-0.55 Mil. The current EBIT is $-0.55 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For Aquarius Surgical Technologies (AQQRF), the current EBIT is $-0.55 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Aquarius Surgical Technologies Business Description

Other Exchanges ASTI:Canada
Address 89 Scollard Street, Toronto, ON, CAN, M5R 1G4
Aquarius Surgical Technologies Inc is engaged in the development, sale, distribution, marketing, and exploitation of laser-driven technologies for use in surgical environments. Through its subsidiary, the company operates as an international distributor, service, and support organization providing integrated laser-based solutions across multiple medical disciplines. These disciplines include urology, gynecology, ophthalmology, thoracic, ENT, cardiovascular, and neurosurgery, many of which are now considered the standard of care for treatment. Geographically, the company generates maximum revenue from the sale of medical devices in the United States, and also has its presence in Canada.